Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Transplantation. 2012 Apr 15;93(7):709-16. doi: 10.1097/TP.0b013e31824612b5.
Endothelial chimerism in transplanted organs can be defined as the presence of recipient-derived endothelial cells in the donor organ. The mechanism of endothelial chimerism is not well understood and remains controversial. The purpose of this study was twofold. First, we investigated the presence of chimerism in renal allografts of ABO-incompatible kidney transplantation recipients. Second, we analyzed the association between chimerism and the clinical course and histopathological changes.
We investigated the presence of chimerism in renal allografts of ABO-incompatible kidney transplantation recipients by immunohistochemical detection of blood type A and B antigens and assessed the association between chimerism, the clinical course, and histopathological changes. Among a total of 56 patients (29 blood group A incompatible and 27 blood group B incompatible), 49 cases (28 blood group A incompatible and 21 blood group B incompatible) were enrolled in this study. Blood group antigens were stained using immunohistochemistry.
Twelve of the 49 patients (12/49, 24.5%) exhibited endothelium chimerism in a biopsy sample. Among the 12 patients with endothelium chimerism, 7 patients (7/12, 59%) had acute and chronic active antibody-mediated rejection and 2 patients (2/12, 17%) had severe calcineurin inhibitor toxicity. The graft survival rate in the chimerism group was significantly lower than that in the no-chimerism group ([chimerism vs. no-chimerism] 3 years, 83.3% vs. 97.1%; 5 years, 74.1% vs. 97.1%; 8 years, 46.3% vs. 97.1%; P<0.0001).
Endothelial chimerism seems to be a hallmark of vigorous immune or nonimmune responses, such as antibody-mediated rejection or calcineurin inhibitor toxicity, and not of the induction of tolerance.
移植器官中的内皮嵌合可以定义为供体器官中存在受者来源的内皮细胞。内皮嵌合的机制尚不清楚,存在争议。本研究的目的有两个。首先,我们调查了 ABO 不相容肾移植受者的肾移植中嵌合体的存在。其次,我们分析了嵌合体与临床病程和组织病理学变化之间的关系。
通过免疫组织化学检测血型 A 和 B 抗原,我们研究了 ABO 不相容肾移植受者的肾移植中嵌合体的存在,并评估了嵌合体、临床病程和组织病理学变化之间的关系。在总共 56 名患者(29 名血型 A 不相容和 27 名血型 B 不相容)中,有 49 名患者(28 名血型 A 不相容和 21 名血型 B 不相容)纳入本研究。使用免疫组织化学染色检测血型抗原。
在 49 例患者的活检样本中,有 12 例(12/49,24.5%)出现内皮嵌合体。在 12 例存在内皮嵌合体的患者中,7 例(7/12,59%)发生急性和慢性活动性抗体介导的排斥反应,2 例(2/12,17%)发生严重钙调神经磷酸酶抑制剂毒性。嵌合体组的移植物存活率明显低于无嵌合体组[嵌合体与无嵌合体比较]3 年,83.3%比 97.1%;5 年,74.1%比 97.1%;8 年,46.3%比 97.1%;P<0.0001)。
内皮嵌合体似乎是强烈的免疫或非免疫反应的标志,如抗体介导的排斥反应或钙调神经磷酸酶抑制剂毒性,而不是诱导耐受的标志。